Sodium-glucose co-transporter 2 inhibitors in heart failure

Autor:	Lars Lund, Giuseppe M.C. Rosano, Yuksel Cavusoglu, Gerasimos Filippatos, Massimo F Piepoli, Frank Ruschitzka, Krishna Prasad, Brenda Moura, Mark C. Petrie, Tiny Jaarsma, Jelena Celutkiene, Marija Polovina, Tuvia Ben Gal, Christian Mueller, Petar M. Seferovic, Gabriele Fragasso, Mitja Lainscak, Stefan Heymans, Marco Metra, Wilfried Mullens, Andrew J.S. Coats, Ovidiu Chioncel, Giuseppe Dattilo, Giuseppe Ambrosio, Pardeep S. Jhund, Alexander R. Lyon, Robin Ray, Thomas Thum, Johann Bauersachs, Piotr Ponikowski, Loreena Hill, Stefan D. Anker, Jelena P. Seferovic, Ewa A. Jankowska, Francesco Cosentino, Rudolf A. de Boer, Roberto Ferrari, Yuri Lopatin
Přispěvatelé:	Cardiovascular Centre (CVC), RS: Carim - H02 Cardiomyopathy, MUMC+: MA Med Staf Spec Cardiologie (9), Cardiologie
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	MECHANISM RATIONALE Type 2 diabetes 030204 cardiovascular system & hematology Ventricular Function Left SGLT2 INHIBITORS chemistry.chemical_compound 0302 clinical medicine SERUM URIC-ACID Medicine Dapagliflozin Canagliflozin Heart failure Sodium–glucose co-transporter 2 inhibitors Type 2 diabetes mellitus Cardiovascular outcomes Quality of life Ejection fraction SGLT2 inhibitors cardiovascular outcomes heart failure quality of life type 2 diabetes Symporters EMPAGLIFLOZIN 3. Good health Cardiology Cardiology and Cardiovascular Medicine medicine.drug Sodium-glucose co-transporter 2 inhibitors medicine.medical_specialty DAPAGLIFLOZIN Glycemic Control 03 medical and health sciences Diabetes mellitus Internal medicine Empagliflozin Humans Sodium-Glucose Transporter 2 Inhibitors business.industry MORTALITY Sodium Type 2 Diabetes Mellitus Stroke Volume DIABETES-MELLITUS KIDNEY-DISEASE medicine.disease Glucose chemistry Diabetes Mellitus Type 2 business RESISTANCE
Zdroj:	European Journal of Heart Failure, 22(9), 1495-1503. Wiley European journal of heart failure, 22(9), 1495-1503. Wiley
ISSN:	1388-9842
Popis:	Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5619d762d08f955c6017343e71b8ad7 https://doi.org/10.1002/ejhf.1954 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.